Description
67934-1-Ig targets AGO2 in WB, IHC, IF, FC (Intra), IP, RIP, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Applications
Positive WB detected in: LNCaP cells, K-562 cells, 4T1 cells, HepG2 cells, HeLa cells, HEK-293 cells, MCF-7 cells, HSC-T6 cells
Positive IHC detected in: human pancreas cancer tissue, human urothelial carcinoma tissueNote: suggested antigen retrieval withTE buffer pH 9.0;(*) Alternatively, antigen retrieval may be performed withcitrate buffer pH 6.0
Positive FC (Intra) detected in: HeLa cells
Recommended dilution
Western Blot (WB): WB : 1:1000-1:5000
Immunohistochemistry (IHC): IHC : 1:200-1:800
Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension
Background Information
EIF2C2, also named as AGO2, belongs to the argonaute family and Ago subfamily. It is required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The 'minimal RISC' appears to include EIF2C2/AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). EIF2C2 may inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. It also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. EIF2C2 can also upregulate the translation of specific mRNAs under certain growth conditions.